Medication info
Valmitaan A Tablets (Valsartan)

Valmitaan A Tablets (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›80mg / 1 tablet
Manufacturer / importer
Korean Pavis Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201207331 · Approved 2012.10.22 · Insurance code 621802330

Summary

Main use
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
1. Essential hypertension Take with water during a meal or between meals. It is recommended that this medicine be taken at the same time each day (e.g., in the morning), if possible. 1) Adults: The recommended dose is 80 mg orally once daily as valsartan, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be coadministered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Initiate treatment with 40 mg once daily of this medicine. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg once daily of this medicine. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg once daily of this medicine. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg once daily of this medicine; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily of this medicine, and the dose may be increased to 80 mg or 160 mg per dose. When coadministered with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy of this medicine with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg twice daily of this medicine; over the following several weeks, increase the dose, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose, administered twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, coadministration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for creatinine clearance of 10 mL/min or more. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If a dose of 80 mg or more per day is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
1. Essential hypertension: Safety and efficacy have not been established in children and adolescents younger than 18 years. 6. Pediatric patients: Safety and efficacy have not been established in children and adolescents younger than 18 years.

Ingredients

Manufacturer
Korean Pavis Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • left ventricular systolic dysfunction
View approved original text

This medication is used to prevent and control hypertension. It is also utilized in the treatment of heart failure patients who have intolerance to ACE inhibitors. Furthermore, it helps reduce the mortality risk in patients with impaired left ventricular function after a myocardial infarction. Therefore, it is used for essential hypertension, heart failure with intolerance to ACE inhibitors, and reduction of mortality risk after myocardial infarction.

How to take

Adult dose

1. Essential hypertension Take with water during a meal or between meals. It is recommended that this medicine be taken at the same time each day (e.g., in the morning), if possible. 1) Adults: The recommended dose is 80 mg orally once daily as valsartan, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be coadministered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Initiate treatment with 40 mg once daily of this medicine. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg once daily of this medicine. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg once daily of this medicine. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg once daily of this medicine; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily of this medicine, and the dose may be increased to 80 mg or 160 mg per dose. When coadministered with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy of this medicine with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg twice daily of this medicine; over the following several weeks, increase the dose, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose, administered twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, coadministration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for creatinine clearance of 10 mL/min or more. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If a dose of 80 mg or more per day is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

1. Essential hypertension: Safety and efficacy have not been established in children and adolescents younger than 18 years. 6. Pediatric patients: Safety and efficacy have not been established in children and adolescents younger than 18 years.

Precautions

This medicine can cause serious harm to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Patients with an allergy to this medication or its ingredients, pregnant or breastfeeding women, and patients with severe liver disease or certain kidney diseases should not take this medicine. Elderly patients, those with elevated potassium levels, weakened liver function, or heart or kidney problems should use this medicine with caution, starting at a low dose and gradually increasing. This medicine lowers blood pressure; thus, when first taking the medication or increasing the dosage, there is a risk of temporary low blood pressure leading to dizziness or fainting. Side effects such as headache, dizziness, fatigue, cough, dyspepsia may occur while taking this medicine, and in rare cases, serious allergic reactions, decreased kidney function, or hyperkalemia may occur, necessitating immediate consultation with a healthcare professional if symptoms appear. Particularly, patients with heart failure or after myocardial infarction should regularly check kidney function, and caution should be exercised if taking this medicine with other antihypertensives, diuretics, or potassium supplements as there is an increased risk of side effects due to interactions. If this medication is taken during pregnancy, tests are needed to check the kidney function and skull development of the fetus, and if breastfeeding, it is recommended to avoid this medication or discontinue breastfeeding. The safety and efficacy of this medication have not been established in children and adolescents under 18 years of age, so it is advisable not to use it. In cases of overdose, severe hypotension or altered consciousness may occur, requiring immediate emergency measures, and it should be stored out of reach of children, not transferred to other containers. While taking this medicine, caution should be taken when driving or operating machinery as dizziness may occur.

Side effects

headache

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, preferably in a cool place below 30 degrees Celsius. Proper storage can help maintain the effectiveness of the drug longer.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.